According to the Canadian Women’s Health Network, most women who don’t smoke, eat well and have a healthy immune system will clear the virus without any treatment. And the Public Health Agency of Canada has said that more than 80 per cent of HPV infections acquired at an early age were gone within a year and a half. Even better, after a woman has fought off a strain, she has almost no chance of contracting it again.
Financial Analysts Judge Merck and Glaxo Sales Growth
May 11, 2009 By Leave a Comment
JPMorgan pharma analyst Chris Schott wrote in a research note to clients Friday, “The larger issue for cervical cancer vaccines in the US is the relative stagnation of the US market. We forecast a decline in US vaccinations (and thus US market sales) in 2009 relative to 2008, with 2010 sales returning to roughly 2008 levels.”
Gardasil, Future Generations Put At Risk
March 30, 2009 By Leave a Comment
In Pursuit of Profit Gardasil is the first virus-like particle (VLP) based vaccine ever approved Researching Merck’s Gardasil HPV vaccine since 2005, I have read through mountains of data, reviewed medical trial results, FDA and CDC press releases, Adverse Reaction Reports, Merck’s Annual Stockholder’s report, and thousands of articles by both Big Phama’s Evangelists and Continue Reading …
BBC Reports Glaxo's Very Profitable HPV Vaccine Contract With UK
June 18, 2008 By Leave a Comment
BBC story diagrams the corporate infighting over which multi-national Pharma Giant wins the very profitable HPV vaccine contract with the UK public health department. Glaxo needed a win big time. Merck has effectively shut them out of the lucrative American market, (the paper work has the FDA logo, but in the ‘Mercky’ world of vaccine politics, Merck lobbyists know how to deliver…a politician, regulator, or an agency, Merck Money moves opinion and decisions.) Merck won’t stop fighting to get a piece of the UK school girl market. Expect continuous stream of Merck public relations rhetoric throughout the balance of 2008 and up to the International Human Papilloma Virus Conference, held in Sweden next June. Both Merck and Glaxo are scheduled to deliver papers. In the Merck world view, “Its not over, until it is over.”
Follow Us!